Akzo Nobel reports second-quarter results:
This article was originally published in Clinica
Dutch chemicals and pharmaceutical company Akzo Nobel has reported sales of Fl 5,618 million ($3,300 million), up 4%, in the second quarter. Net income was down 4% to Fl 367 million. The pharmaceutical division's revenues rose 4% to Fl 996 million, and Organon Teknika, part of this division, suffered declining product volumes because of negative scientific reports on certain oral contraceptives during the period.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.